(CLS) Celestica - Ratings and Ratios
Electronics, Hardware, Supply Chain, Manufacturing, After-Market
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 73.5% |
| Value at Risk 5%th | 117% |
| Relative Tail Risk | -3.11% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.01 |
| Alpha | 235.42 |
| CAGR/Max DD | 3.94 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.524 |
| Beta | 2.232 |
| Beta Downside | 2.478 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.96% |
| Mean DD | 8.75% |
| Median DD | 4.78% |
Description: CLS Celestica October 14, 2025
Celestica Inc. (NYSE:CLS) delivers end-to-end supply-chain solutions across Asia, North America and global markets, organized into two operating segments: Advanced Technology Solutions and Connectivity & Cloud Solutions.
The firm’s service portfolio spans product design, new-product introduction, engineering, component sourcing, electronics manufacturing & assembly, testing, mechanical assembly, systems integration, precision machining, order fulfillment, logistics, asset management, product licensing, and aftermarket repair/return. It also offers hardware platform services-including infrastructure platform development, hardware/software design (including open-source code), and full-cycle program management from design through IT asset disposition.
Celestica serves a diversified client base of OEMs, hyperscale cloud providers, and companies in aerospace & defense, industrial, HealthTech, capital equipment, communications, and enterprise sectors.
Key metrics (FY 2024): revenue of $5.8 billion, operating margin of 4.9 %, and free cash flow conversion of 78 %. The company’s order backlog stood at $6.3 billion, indicating a 12 % YoY increase, while its contract-manufacturing exposure to hyperscalers grew to ≈ 30 % of total revenue.
Sector drivers that materially affect Celestica include the ongoing global chip shortage, which pressures lead times and pricing; the acceleration of cloud-infrastructure spend (projected CAGR ≈ 9 % through 2028); and macro-level trends in reshoring and near-shoring that can shift demand toward North-American EMS providers.
For a data-rich, comparative view of Celestica’s valuation and risk profile, you may find ValueRay’s analyst toolkit useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (697.0m TTM) > 0 and > 6% of Revenue (6% = 674.8m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -0.68pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 14.59% (prev 15.50%; Δ -0.91pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 482.1m <= Net Income 697.0m (YES >=105%, WARN >=100%) |
| Net Debt (478.2m) to EBITDA (1.03b) ratio: 0.47 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.47 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (115.9m) change vs 12m ago -2.52% (target <= -2.0% for YES) |
| Gross Margin 11.58% (prev 10.37%; Δ 1.21pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 179.5% (prev 155.9%; Δ 23.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 22.10 (EBITDA TTM 1.03b / Interest Expense TTM 40.3m) >= 6 (WARN >= 3) |
Altman Z'' 2.69
| (A) 0.25 = (Total Current Assets 5.14b - Total Current Liabilities 3.50b) / Total Assets 6.61b |
| (B) 0.02 = Retained Earnings (Balance) 141.2m / Total Assets 6.61b |
| (C) 0.14 = EBIT TTM 889.8m / Avg Total Assets 6.27b |
| (D) 0.03 = Book Value of Equity 141.2m / Total Liabilities 4.58b |
| Total Rating: 2.69 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 84.21
| 1. Piotroski 6.0pt |
| 2. FCF Yield 1.00% |
| 3. FCF Margin 2.92% |
| 4. Debt/Equity 0.39 |
| 5. Debt/Ebitda 0.47 |
| 6. ROIC - WACC (= 14.89)% |
| 7. RoE 38.51% |
| 8. Rev. Trend 97.65% |
| 9. EPS Trend 97.92% |
What is the price of CLS shares?
Over the past week, the price has changed by +2.11%, over one month by +0.93%, over three months by +33.05% and over the past year by +259.53%.
Is CLS a buy, sell or hold?
- Strong Buy: 6
- Buy: 6
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CLS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 374.2 | 15.1% |
| Analysts Target Price | 374.2 | 15.1% |
| ValueRay Target Price | 478.3 | 47.1% |
CLS Fundamental Data Overview November 25, 2025
P/E Trailing = 45.4643
P/E Forward = 34.2466
P/S = 2.8557
P/B = 15.8815
P/EG = 19.42
Beta = 1.507
Revenue TTM = 11.25b USD
EBIT TTM = 889.8m USD
EBITDA TTM = 1.03b USD
Long Term Debt = 756.7m USD (from longTermDebt, last quarter)
Short Term Debt = 27.4m USD (from shortTermDebt, last quarter)
Debt = 784.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 478.2m USD (from netDebt column, last quarter)
Enterprise Value = 32.70b USD (32.22b + Debt 784.1m - CCE 305.9m)
Interest Coverage Ratio = 22.10 (Ebit TTM 889.8m / Interest Expense TTM 40.3m)
FCF Yield = 1.00% (FCF TTM 328.4m / Enterprise Value 32.70b)
FCF Margin = 2.92% (FCF TTM 328.4m / Revenue TTM 11.25b)
Net Margin = 6.20% (Net Income TTM 697.0m / Revenue TTM 11.25b)
Gross Margin = 11.58% ((Revenue TTM 11.25b - Cost of Revenue TTM 9.94b) / Revenue TTM)
Gross Margin QoQ = 11.62% (prev 12.82%)
Tobins Q-Ratio = 4.95 (Enterprise Value 32.70b / Total Assets 6.61b)
Interest Expense / Debt = 1.61% (Interest Expense 12.7m / Debt 784.1m)
Taxrate = 13.86% (42.6m / 307.5m)
NOPAT = 766.5m (EBIT 889.8m * (1 - 13.86%))
Current Ratio = 1.47 (Total Current Assets 5.14b / Total Current Liabilities 3.50b)
Debt / Equity = 0.39 (Debt 784.1m / totalStockholderEquity, last quarter 2.03b)
Debt / EBITDA = 0.47 (Net Debt 478.2m / EBITDA 1.03b)
Debt / FCF = 1.46 (Net Debt 478.2m / FCF TTM 328.4m)
Total Stockholder Equity = 1.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.55% (Net Income 697.0m / Total Assets 6.61b)
RoE = 38.51% (Net Income TTM 697.0m / Total Stockholder Equity 1.81b)
RoCE = 34.67% (EBIT 889.8m / Capital Employed (Equity 1.81b + L.T.Debt 756.7m))
RoIC = 28.82% (NOPAT 766.5m / Invested Capital 2.66b)
WACC = 13.93% (E(32.22b)/V(33.00b) * Re(14.24%) + D(784.1m)/V(33.00b) * Rd(1.61%) * (1-Tc(0.14)))
Discount Rate = 14.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.52%
[DCF Debug] Terminal Value 63.72% ; FCFE base≈331.1m ; Y1≈405.7m ; Y5≈681.4m
Fair Price DCF = 43.78 (DCF Value 5.04b / Shares Outstanding 115.0m; 5y FCF grow 24.10% → 3.0% )
EPS Correlation: 97.92 | EPS CAGR: 40.62% | SUE: 3.06 | # QB: 10
Revenue Correlation: 97.65 | Revenue CAGR: 21.71% | SUE: 1.85 | # QB: 3
EPS next Quarter (2026-03-31): EPS=1.83 | Chg30d=+0.249 | Revisions Net=+12 | Analysts=13
EPS next Year (2026-12-31): EPS=8.38 | Chg30d=+1.303 | Revisions Net=+13 | Growth EPS=+41.3% | Growth Revenue=+32.9%
Additional Sources for CLS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle